Metabolite Profiling and Identification Studies
Metabolite profiling and identification (MetID) studies are of great value in analyzing the pharmacological, pharmacokinetic, and toxicological properties of drugs. Our company provides comprehensive metabolite profiling and identification services, including radioisotope-labeled metabolite profiling and identification. Our services cover all stages of preclinical research for rare disease drug development.
Introduction to Metabolite Profiling and Identification
Metabolite profiling and identification (MetID) refers to the analysis, separation, determination, and identification of metabolites in biological matrices. MetID is a qualitative and quantitative study of drugs in biotransformation.
After entering the human body, drugs undergo biotransformation and are eliminated by excretion or metabolism to form one or more metabolites. Drugs may produce pharmacologically inactive drugs, pharmacologically active drugs, and even toxic metabolites after biotransformation in the body. Metabolite profiling and identification are key components in understanding the efficacy and safety of drugs.
Fig.1 Application of metabolite profiling in drug design and discovery. (Cerny, M A., et al., 2020) Metabolite analysis and identification contribute to metabolite screening and new drug development and play a key role in rare disease drug discovery.
Our Services
With capabilities covering a wide range of compound types, our company provides complete in vivo metabolite research services, including natural products, small molecules, nucleotide compounds, macromolecular polysaccharides, peptides, ADCs, proteolysis targeting chimera, oligonucleotides, etc. Our team of experts can provide one-stop services for in vivo metabolite research based on your specific requirements.
- Content of MetID
The content our company can provide for MetID studies includes but is not limited to:
- Structure elucidation of metabolites
- Studies of the metabolic pathways
- Determination of relative abundance of metabolites
- Methods of MetID
The methods our company can provide for MetID studies include but are not limited to:
- High-performance Liquid Chromatography (HPLC)
- High-resolution Mass Spectrometry (MS)
- Ultra-performance Liquid Chromatography (UPLC)
- High-throughput Nuclear Magnetic Resonance (NMR)
- Quadrupole Time-of-Flight (QTOF)
- Capillary Electrophoresis (CE)
- Thin Layer Chromatography (TLC)
- Ion Mobility Separation (IMS)
- Workflow of MetID
In vivo experiments
Providing a variety of animal species and designs reasonable in vivo test protocols according to customer requirements.
Sample preparation
Identification of metabolites in complex matrices such as plasma, urine, feces, bile, and tissues in the body.
Metabolite analysis
Providing sophisticated instruments, including LC-MS and LC-MS/MS, for metabolite analysis and structural identification of various sample types.
Data analysis
Combining chromatography and mass spectrometry data analysis software for data analysis, our company provides excellent after-sales support.
In addition to in vivo metabolite profiling and identification studies, our company also provides in vitro metabolite studies, including in vitro metabolite identification of microsomes, S9, lysosomes, recombinant enzymes, hepatocytes, plasma, etc.
Why Choose Us?
- Careful design and transparent operation process
- Competitive pricing and fast turnaround time
- Automation-friendly workflow
- High data quality and reliable analysis
- Exceptional post-sales support
As an integrated CRO, our company has extensive expertise in pharmacokinetics for rare disease research, particularly in metabolite profiling and identification studies. We have the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease research projects. If you are interested in our services, please feel free to contact us for more information.
Reference
- Cerny, M A., et al., "Effective application of metabolite profiling in drug design and discovery." Journal of Medicinal Chemistry 63.12 (2020): 6387-6406.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.